Alnylam Pharmaceuticals, Inc. Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
71.9%projected annual EPS growth
Analyst Coverage
25analysts covering
FY Revenue (est.)
$5.5Bnext fiscal year
FY EPS (est.)
$8.92next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Next Earnings Release | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly total net product revenue (USD millions) Quarterly1.2KTarget: FY2026 guidance: $4.7-$5.1 billion
Quarterly total TTR net product revenue (USD millions) Quarterly1KTarget: FY2026 guidance: $4.2-$4.5 billion
Quarterly total Rare net product revenue (USD millions) Quarterly141.9Target: FY2026 guidance: $0.5-$0.6 billion
Watch Items
- Full-year TTR franchise performance following normalization of U.S. second-line AMVUTTRA demand
- Execution of the announced second-half 2026 clinical-readout program
Research as of 29 Aug 2026